Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sees Large Growth in Short Interest

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 649,723 shares, a growth of 139.7% from the July 15th total of 271,067 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 252 shares, the short-interest ratio is currently 2,578.3 days.

Wall Street Analysts Forecast Growth

BIOVF has been the subject of several research analyst reports. Zacks Research upgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, May 7th. Pareto Securities cut Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Finally, HC Wainwright initiated coverage on Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating for the company. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Swedish Orphan Biovitrum has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

OTCMKTS:BIOVF opened at $48.20 on Friday. The stock’s 50-day simple moving average is $48.32 and its 200 day simple moving average is $43.85. Swedish Orphan Biovitrum has a 52-week low of $28.93 and a 52-week high of $49.03. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The company has a market cap of $17.16 billion, a P/E ratio of 107.12 and a beta of 0.35.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.